Efficacy and Safety of Tazarotene Gel in Nail Psoriasis

A Phase II Trial to Evaluate the Anti-psoriatic Efficacy and Tolerability of Tazarotene in a Gel Formulation in Patients With Mild to Moderate Nail Psoriasis - Parallel Group Comparison

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02235480

Enrollment

Registered

2014-09-10

Start date

2014-02-28

Completion date

2015-05-31

Last updated

2015-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nail Psoriasis

Brief summary

The aim of this study is to determine the efficacy and safety of topical application of the gel compared to placebo in nail psoriasis.

Interventions

DRUGExperimental Tazarotene Gel

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Key inclusion criteria: * Mild to moderate nail psoriasis on at least one fingernail

Exclusion criteria

Key

Design outcomes

Primary

Measure	Time frame
% reduction in the Nail Psoriasis Severity Index ( NAPSI )	Day85

Secondary

Measure	Time frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Day 85

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026